Financials data is unavailable for this security.
View more
Year on year Bide Pharmatech Co Ltd had net income fall -24.94% from 145.97m to 109.57m despite a 30.94% increase in revenues from 833.83m to 1.09bn. An increase in the cost of goods sold as a percentage of sales from 56.52% to 61.67% was a component in the falling net income despite rising revenues.
Gross margin | 38.92% |
---|---|
Net profit margin | 6.96% |
Operating margin | 8.42% |
Return on assets | 3.26% |
---|---|
Return on equity | 3.86% |
Return on investment | 3.73% |
More ▼
Cash flow in CNYView more
In 2023, cash reserves at Bide Pharmatech Co Ltd fell by 230.39m. Cash Flow from Investing was negative at 28.87m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 57.39m for operations while cash used for financing totalled 138.31m.
Cash flow per share | -- |
---|---|
Price/Cash flow per share | -- |
Book value per share | 21.73 |
---|---|
Tangible book value per share | 21.69 |
More ▼
Balance sheet in CNYView more
Current ratio | 7.35 |
---|---|
Quick ratio | 5.04 |
Total debt/total equity | 0.045 |
---|---|
Total debt/total capital | 0.043 |
More ▼